Last reviewed · How we verify
HB/APAP
HB/APAP is a combination therapy that pairs a hepatitis B antigen with acetaminophen to modulate immune responses against hepatitis B infection.
HB/APAP is a combination therapy that pairs a hepatitis B antigen with acetaminophen to modulate immune responses against hepatitis B infection. Used for Chronic hepatitis B infection.
At a glance
| Generic name | HB/APAP |
|---|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
This investigational combination leverages a hepatitis B surface antigen component to stimulate immune recognition of HBV, potentially combined with acetaminophen's immunomodulatory properties. The exact mechanism remains proprietary to Vertex, but the approach appears designed to enhance viral clearance or functional cure in chronic hepatitis B patients.
Approved indications
- Chronic hepatitis B infection
Common side effects
Key clinical trials
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- An Efficacy and Safety Study of LTG-001 Following Abdominoplasty (PHASE2)
- Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy (PHASE3)
- Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty (PHASE3)
- A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy (PHASE2)
- A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy (PHASE2)
- A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty (PHASE2)
- A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB/APAP CI brief — competitive landscape report
- HB/APAP updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI